16,850 Shares in Celcuity, Inc. $CELC Purchased by Legal & General Group Plc

Legal & General Group Plc acquired a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 16,850 shares of the company’s stock, valued at approximately $1,763,000.

Several other large investors also recently added to or reduced their stakes in the stock. California State Teachers Retirement System increased its position in shares of Celcuity by 91.2% during the first quarter. California State Teachers Retirement System now owns 25,580 shares of the company’s stock worth $2,920,000 after acquiring an additional 12,201 shares during the period. Hsbc Holdings PLC purchased a new stake in shares of Celcuity in the fourth quarter valued at approximately $1,058,000. Geode Capital Management LLC boosted its holdings in shares of Celcuity by 8.4% in the fourth quarter. Geode Capital Management LLC now owns 830,684 shares of the company’s stock valued at $82,872,000 after purchasing an additional 64,213 shares during the period. TD Asset Management Inc grew its stake in Celcuity by 34.0% in the fourth quarter. TD Asset Management Inc now owns 97,526 shares of the company’s stock worth $9,727,000 after purchasing an additional 24,730 shares in the last quarter. Finally, E Fund Management Co. Ltd. purchased a new position in Celcuity during the 2nd quarter worth $4,802,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on CELC shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research report on Tuesday, September 1st. Stifel Nicolaus cut their price target on Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Guggenheim raised their price target on Celcuity from $165.00 to $175.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Needham & Company LLC lowered their price objective on shares of Celcuity from $157.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, Craig Hallum reiterated a “buy” rating and set a $178.00 target price on shares of Celcuity in a report on Wednesday, July 15th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $154.55.

Celcuity Stock Performance

Shares of NASDAQ CELC opened at $95.70 on Monday. Celcuity, Inc. has a 1-year low of $44.42 and a 1-year high of $151.02. The business has a fifty day moving average price of $94.58 and a 200 day moving average price of $106.78. The stock has a market capitalization of $4.68 billion, a P/E ratio of -22.26 and a beta of 0.19. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93.

Celcuity (NASDAQ:CELC) last posted its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). Equities research analysts expect that Celcuity, Inc. will post -4.75 EPS for the current fiscal year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.